A planned secondary analysis of the Insulin Resistance Intervention After Stroke (IRIS) study helps to identify patients who are most likely to benefit from treatment with pioglitazone (Actos, Takeda ...

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the trial suggest a potential new ...

LOS ANGELES — New randomized trial results show that in patients with insulin resistance, no frank diabetes, and a history of stroke or transient ischemic attack, treatment with diabetes drug ...

In insulin-resistant patients who had a recent ischemic stroke or transient ischemic attack, treatment with the diabetes drug pioglitazone was associated with lower risk for stroke or MI compared with ...